Table 4 Pathways enriched in schizophrenia and smoking traits.
From: Genetic Relationship between Schizophrenia and Nicotine Dependence
Pathway | Genes found in pathway | # gene in pathway | # gene observed | # gene expected | Observed/expected ratio | Raw P-value | Adjusted P-value |
|---|---|---|---|---|---|---|---|
Calcium signaling pathway | ATP2B2, CACNA1C, CACNA1I, CHRM3, ITPR1, ITPR2 | 177 | 6 | 0.57 | 10.59 | 2.41E-05 | 0.0004 |
Long-term potentiation | CACNA1C, ITPR1, ITPR2, PPP1CB | 70 | 4 | 0.22 | 17.86 | 7.81E-05 | 0.0007 |
Neuroactive ligand-receptor interaction | CHRM3, CHRNA3, CHRNA5, CHRNB4, NR3C1, THRB | 272 | 6 | 0.87 | 6.89 | 0.0003 | 0.0011 |
Salivary secretion | ATP2B2, CHRM3, ITPR1, ITPR2 | 89 | 4 | 0.28 | 14.05 | 0.0002 | 0.0011 |
Pancreatic secretion | ATP2B2, CHRM3, ITPR1, ITPR2 | 101 | 4 | 0.32 | 12.38 | 0.0003 | 0.0011 |
Vascular smooth muscle contraction | CACNA1C, ITPR1, ITPR2, PPP1CB | 116 | 4 | 0.37 | 10.78 | 0.0005 | 0.0013 |
Oocyte meiosis | ITPR1, ITPR2, PPP1CB, SPDYA | 112 | 4 | 0.36 | 11.16 | 0.0005 | 0.0013 |
Phosphatidylinositol signaling system | INPP5K, ITPR1, ITPR2 | 78 | 3 | 0.25 | 12.02 | 0.0020 | 0.0036 |
Gastric acid secretion | CHRM3, ITPR1, ITPR2 | 74 | 3 | 0.24 | 12.67 | 0.0018 | 0.0036 |
Arrhythmogenic right ventricular cardiomyopathy (ARVC) | CACNA1C, ITGAV, SGCD | 74 | 3 | 0.24 | 12.67 | 0.0018 | 0.0036 |
Hypertrophic cardiomyopathy (HCM) | CACNA1C, ITGAV, SGCD | 83 | 3 | 0.27 | 11.30 | 0.0024 | 0.0039 |
Dilated cardiomyopathy | CACNA1C, ITGAV, SGCD | 90 | 3 | 0.29 | 10.42 | 0.0031 | 0.0046 |
GnRH signaling pathway | CACNA1C, ITPR1, ITPR2 | 101 | 3 | 0.32 | 9.28 | 0.0042 | 0.0058 |
Cell adhesion molecules (CAMs) | ITGAV, NCAM2, PTPRM | 133 | 3 | 0.43 | 7.05 | 0.0091 | 0.0117 |
Alzheimer’s disease | CACNA1C, ITPR1, ITPR2 | 167 | 3 | 0.53 | 5.61 | 0.0167 | 0.0188 |
Regulation of actin cytoskeleton | CHRM3, ITGAV, PPP1CB | 213 | 3 | 0.68 | 4.40 | 0.0313 | 0.0331 |
